Study of the bioavilability of triterpenoids from pomace oil and their role on processes involved in the formation of the atheroclerotic plaque

A double-blind, randomised controlled trial to assess the bioavilability of triterpenoids from pomace oil and their role on processes involved in the formation of the atheroclerotic plaque

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN22685192

Enrollment

Registered

2011-06-16

Start date

2009-01-01

Completion date

Unknown

Last updated

2015-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Atherosclerosis Nutritional, Metabolic, Endocrine Atherosclerosis

Interventions

1. Administration of meals in fasting conditions 2. Each meal will provide the same nutrient compositon but the fat source will change 3. Three different fat sources will be compared: 3.1. Virgin oli

Eligibility

Sex/Gender

Male

Inclusion criteria

Inclusion criteria: Healthy males not suffering from hypertriglyceridemia

Exclusion criteria

Exclusion criteria: 1. Age lower than 18 years and higher than 55 years 2. Hypertriglyceridemia 3. Hypertension 4. Coronary heart disease (CHD) 5. Renal or hepatic disease 6. Obesity 7. Diabetes 8. Alcoholism 9. Smoking 10. Under pharmacological treatment affecting lipid metabolism, coagulation or any condition of the study

Design outcomes

Primary

Measure	Time frame
1. Postprandial lipid composition of triglyceride-rich lipoproteins 2. Presence and concentration of oleanolic acid in serum and triglyceride-rich lipoproteins	—

Secondary

Measure	Time frame
1. Foam cell formation from macrophages (THP-1 cell line) after treatment with postpandial triglyceride-rich lipoproteins 2. Release of inflammation markers by macrophages (THP-1 cell line) after treatment with postpandial triglyceride-rich lipoproteins 3. Receptor expression in macrophages (THP-1 cell line) after treatment with postpandial triglyceride-rich lipoproteins	—

Countries

Spain

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026